Da Liu, managing director of CR-CP Life Science Fund, emphasizes China's recent biotech breakthroughs as proof that innovation can lower healthcare costs and expand access.

Multinational companies view Chinese biotech assets as strategic opportunities, recognizing their growing influence in the global market.

Since its launch in 2019 with $170 million, the CR-CP Life Science Fund has supported companies like Legend Biotech and Mirxes, which have successfully gone public in the US and Hong Kong.

Chinese biotech innovations are increasingly attracting licensing interest from global firms due to their cost advantages, quicker development timelines, and high quality.

China's biotech sector is emerging as a cost-effective alternative to Western healthcare products, with the potential to reduce healthcare costs worldwide.